Saturday, April 27 marks the DEA's National Drug Take Back Day. In the lead-up to that event, the FDA just launched a drug safety campaign aimed at opioid abuse prevention.
Patient Safety Key as NACDS and APhA Oppose Prescription Drug Importation Emphasize commitment to safer, more effective strategies to reduce drug prices and increase access to prescription medications
NACDS and the American Pharmacists Association (APhA) expressed concerns about the risks to patient health and the security of the prescription drug supply chain in opposing legislation that would allow for personal and commercial importation of prescription drugs outside of the Food and Drug Administration’s (FDA) oversight.
The Food and Drug Administration (FDA) took action this week targeting 465 websites that illegally sell potentially dangerous, unapproved versions of opioids, cancer and antiviral prescription drugs to U.S. consumers.
The Senate agreed to vote this week on a legislative package—the Opioid Crisis Response Act of 2018—to combat the opioid abuse crisis, which includes an NACDS-backed e-prescribing bill.
NACDS was highly engaged in the Opioid Crisis Solutions Summit in Washington, D.C., last month, which released a roadmap this week with recommendations on combating the opioid abuse crisis.
During a Senate Finance Committee hearing on opioid abuse prevention, senators pointed to the benefits of e-prescribing legislation as part of the solution in combating the opioid abuse epidemic. The bill later advanced.
NACDS RxIMPACT launched a grasstops campaign this week encouraging pharmacy advocates to urge support for the Pharmacy and Medically Underserved Areas Enhancement Act.
NACDS provided recommendations on policy changes to the House Energy and Commerce Committee during this week's congressional hearing on combating the opioid abuse epidemic.